This document discusses Parkinson's disease and its treatment with L-DOPA and carbidopa. Parkinson's is characterized by the death of dopaminergic neurons in the brain, resulting in movement issues from low dopamine levels. L-DOPA is converted to dopamine in the brain by the enzyme tyrosine hydroxylase, while carbidopa inhibits tyrosine hydroxylase outside the brain to prevent side effects from excess dopamine elsewhere. The combination treatment localizes the therapeutic effects of dopamine production to the brain.